Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Retrospective, observational cohort analysis using VA data* between October 1, 2013 and September 30, 2018

Included

Age ≥18 with an inpatient or outpatient VTE diagnosis at a VA site (determined via ICD-9/10-CM codes)
DOAC or warfarin prescription within 30 days of the index VTE event

Excluded

Prior VTE (within 4 years before index VTE)
AF or mechanical heart valve in the 2 years prior to or up to 30 days after index VTE
>1 OAC prescribed on the date of index VTE treatment^†
No weight measurements ±90 days of the index VTE
No height measurements ±4 years of the index VTE
Any weight measurement inconsistent with adjacent weight measurements
Missing sex variable
Outlier weight measurements (<34.1 kg and >318.2 kg) and height measurements (<1.2 m and >2.1 m)

1|2

* Includes records from (1) the VA National Patient Care Database; (2) the VA Decision Support System National Pharmacy Extract; (3) the VA Fee Basis Inpatient and Outpatient data sets; (4) the VA Laboratory Decision Support System Extract; (5) Medicare inpatient and outpatient institutional claims data (Part A, Part B, and carrier files); (6) the VA Vital Status File, which contains validated combined mortality data from VA, Medicare, and Social Security Administration sources; and (7) the VA Vital Sign File, which contains patient weight and height measurements obtained during routine care.
^†The index VTE treatment date was defined as the date of first anticoagulant prescription, whether it was oral or parenteral.

AF, atrial fibrillation; DOAC, direct oral anticoagulant; ICD-9/10-CM, International Classification of Diseases, 9th/10th Revision, Clinical Modification;
LMWH/F, low-molecular-weight heparin or fondaparinux; OAC, oral anticoagulant; VA, Veterans Health Administration; VTE, venous thromboembolism.

Methods1

Methods¹